BIRC5 and neuroblastoma: Hence, survivin is particularly promising as drug target for the treatment of p53 wild-type neuroblastomas, including neuroblastomas with acquired resistance to clinically relevant anticancer drugs, potentially in combination with p53 activators such as MDM2 inhibitors that further enhance YM155 activity.